-
1
-
-
84876459504
-
Contrast-induced acute kidney injury following PCI
-
PID: 23441924
-
Tehrani S, et al. Contrast-induced acute kidney injury following PCI. Eur J Clin Invest. 2013;43:483–90.
-
(2013)
Eur J Clin Invest
, vol.43
, pp. 483-490
-
-
Tehrani, S.1
-
2
-
-
84898667280
-
Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention
-
PID: 24630389
-
Tziakas D, et al. Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. Am J Cardiol. 2014;113:1487–93.
-
(2014)
Am J Cardiol
, vol.113
, pp. 1487-1493
-
-
Tziakas, D.1
-
3
-
-
10744221196
-
Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction
-
PID: 14638545
-
Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769–75.
-
(2003)
Circulation
, vol.108
, pp. 2769-2775
-
-
Sadeghi, H.M.1
Stone, G.W.2
Grines, C.L.3
-
4
-
-
84959309333
-
Aggressive hydraTion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention to prevent contrast-induced nephropathy (ATTEMPT): study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy following carDiac catheterization) trial
-
PID: 26856220
-
Liu M, et al. Aggressive hydraTion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention to prevent contrast-induced nephropathy (ATTEMPT): study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy following carDiac catheterization) trial. Am Heart J. 2016;172:88–95.
-
(2016)
Am Heart J
, vol.172
, pp. 88-95
-
-
Liu, M.1
-
5
-
-
81255167971
-
Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty
-
PID: 21710343
-
Droppa M, Desch S, Blase P, et al. Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol. 2011;100:1037–43.
-
(2011)
Clin Res Cardiol
, vol.100
, pp. 1037-1043
-
-
Droppa, M.1
Desch, S.2
Blase, P.3
-
6
-
-
84900438757
-
Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial
-
PID: 24714489
-
Thayssen P, Lassen JF, Jensen SE, et al. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv. 2014;7:216–24.
-
(2014)
Circ Cardiovasc Interv
, vol.7
, pp. 216-224
-
-
Thayssen, P.1
Lassen, J.F.2
Jensen, S.E.3
-
7
-
-
84994430570
-
The effect of spironolactone on acute kidney injury after cardiac surgery: a randomized, placebo-controlled trial
-
Navarro RB, et al. The effect of spironolactone on acute kidney injury after cardiac surgery: a randomized, placebo-controlled trial. Am J Kidney Dis. 2016. 10.1053/j.ajkd.2016.06.013.
-
(2016)
Am J Kidney Dis
-
-
Navarro, R.B.1
-
8
-
-
34548012161
-
Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone
-
PID: 17376767
-
Mejia-Vilet JM, et al. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol. 2007;293:F78–86.
-
(2007)
Am J Physiol Renal Physiol
, vol.293
, pp. F78-F86
-
-
Mejia-Vilet, J.M.1
-
9
-
-
84864585183
-
Recovery from ischemic acute kidney injury by spironolactone administration
-
PID: 22516623
-
Sanchez-Pozos K, et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant. 2012;27:3160–9.
-
(2012)
Nephrol Dial Transplant
, vol.27
, pp. 3160-3169
-
-
Sanchez-Pozos, K.1
-
10
-
-
84866559183
-
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery
-
PID: 22824930
-
Pretorius M, et al. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med. 2012;40(10):2805–12.
-
(2012)
Crit Care Med
, vol.40
, Issue.10
, pp. 2805-2812
-
-
Pretorius, M.1
-
11
-
-
77953125953
-
Cystatin C and contrast-induced acute kidney injury
-
PID: 20439784
-
Briguori C, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121:2117–22.
-
(2010)
Circulation
, vol.121
, pp. 2117-2122
-
-
Briguori, C.1
-
12
-
-
84884342549
-
Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury
-
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, Herzog CA, Joannidis M, Kribben A, Levey AS, MacLeod AM, Mehta RL, Murray PT, Naicker S, Opal SM, Schaefer F, Schetz M, Uchino S. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1–138.
-
(2012)
Kidney Int Suppl
, vol.2
, pp. 1-138
-
-
Kellum, J.A.1
Lameire, N.2
Aspelin, P.3
Barsoum, R.S.4
Burdmann, E.A.5
Goldstein, S.L.6
Herzog, C.A.7
Joannidis, M.8
Kribben, A.9
Levey, A.S.10
MacLeod, A.M.11
Mehta, R.L.12
Murray, P.T.13
Naicker, S.14
Opal, S.M.15
Schaefer, F.16
Schetz, M.17
Uchino, S.18
-
13
-
-
84942067715
-
Neutrophil gelatinase-associated lipocalin in the prediction of contrast-induced nephropathy: a systematic review and meta-analysis
-
PID: 25915514
-
Tong J, et al. Neutrophil gelatinase-associated lipocalin in the prediction of contrast-induced nephropathy: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2015;66:239–45.
-
(2015)
J Cardiovasc Pharmacol
, vol.66
, pp. 239-245
-
-
Tong, J.1
-
15
-
-
85032636181
-
Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial
-
Butler J, Anstrom KJ, Feller M, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017. 10.1001/jamacardio.2017.2198.
-
(2017)
JAMA Cardiol
-
-
Butler, J.1
Anstrom, K.J.2
Feller, M.3
-
16
-
-
85118094244
-
The role of serum cystatin C in the early detection of contrast-induced nephropathy after coronary intervention
-
Al-Tu’ma FJ, et al. The role of serum cystatin C in the early detection of contrast-induced nephropathy after coronary intervention. J Kidney. 2017;3:154. 10.4172/2472-1220.1000154.
-
(2017)
J Kidney
, vol.3
, pp. 154
-
-
Al-Tu’ma, F.J.1
-
17
-
-
85118089246
-
Contrast-induced nephropathy in diabetic and non-diabetic patients after coronary intervention
-
Nassir FS. Contrast-induced nephropathy in diabetic and non-diabetic patients after coronary intervention. J Babylon Univ/Pure Appl Sci. 2014;22(9):2530–46.
-
(2014)
J Babylon Univ/Pure Appl Sci
, vol.22
, Issue.9
, pp. 2530-2546
-
-
Nassir, F.S.1
-
18
-
-
84947485037
-
Predicting contrast-induced nephropathy post coronary intervention: a prospective cohort study
-
Taher, et al. Predicting contrast-induced nephropathy post coronary intervention: a prospective cohort study. Egypt Heart J. 2015;67:337–43.
-
(2015)
Egypt Heart J
, vol.67
, pp. 337-343
-
-
Taher1
-
19
-
-
84943302679
-
Risk prediction models for contrast-induced nephropathy: systematic review
-
PID: 26316642
-
Silver SA, et al. Risk prediction models for contrast-induced nephropathy: systematic review. BMJ. 2015;351:h4395.
-
(2015)
BMJ
, vol.351
, pp. h4395
-
-
Silver, S.A.1
-
20
-
-
84959145241
-
How strong is the evidence for sodium bicarbonate to prevent contrast-induced acute kidney injury after coronary angiography and percutaneous coronary intervention?
-
PID: 26886610
-
Dong Y, et al. How strong is the evidence for sodium bicarbonate to prevent contrast-induced acute kidney injury after coronary angiography and percutaneous coronary intervention? Medicine. 2016;95(7):e2715.
-
(2016)
Medicine
, vol.95
, Issue.7
-
-
Dong, Y.1
-
21
-
-
84901244167
-
Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial
-
PID: 24856027
-
Brar SS, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814–23.
-
(2014)
Lancet
, vol.383
, Issue.9931
, pp. 1814-1823
-
-
Brar, S.S.1
-
22
-
-
84981736365
-
Rationale and design of the aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure (ATHENA-HF) trial
-
PID: 27522631
-
Butler J, et al. Rationale and design of the aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure (ATHENA-HF) trial. JACC Heart Fail. 2016;4(9):726–35.
-
(2016)
JACC Heart Fail
, vol.4
, Issue.9
, pp. 726-735
-
-
Butler, J.1
-
23
-
-
84892811303
-
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure
-
PID: 24070521
-
Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med. 2014;25:67–72.
-
(2014)
Eur J Intern Med
, vol.25
, pp. 67-72
-
-
Ferreira, J.P.1
Santos, M.2
Almeida, S.3
Marques, I.4
Bettencourt, P.5
Carvalho, H.6
-
24
-
-
0020443385
-
Spironolactone dose–response relationships in healthy subjects
-
McInnes CT, et al. Spironolactone dose–response relationships in healthy subjects. Br J Clin Pharm. 1982;13:513–8.
-
(1982)
Br J Clin Pharm
, vol.13
, pp. 513-518
-
-
McInnes, C.T.1
|